Presentation is loading. Please wait.

Presentation is loading. Please wait.

PERFORMANCE REVIEW: Q3FY13 INVESTOR UPDATE. Presentation Path Aarti Industries – Profile Core Strengths Segmental overview Q3 FY13 Segmental Performance.

Similar presentations


Presentation on theme: "PERFORMANCE REVIEW: Q3FY13 INVESTOR UPDATE. Presentation Path Aarti Industries – Profile Core Strengths Segmental overview Q3 FY13 Segmental Performance."— Presentation transcript:

1 PERFORMANCE REVIEW: Q3FY13 INVESTOR UPDATE

2 Presentation Path Aarti Industries – Profile Core Strengths Segmental overview Q3 FY13 Segmental Performance Condensed Statement of Operations Segmental Revenue Growth Trend Q3 FY13 Financial Highlights Segmental Revenue Growth Trend Financial Highlights – over 6 quarters Financial Highlights – Graphical Highlights Key Developments – Q3 FY13 New Investment Plans Annexure / Back-up slides – Financial Statements 2

3 Leading manufacturer of Speciality Chemicals & Pharmaceuticals with diversified end-uses in Pharmaceuticals, Agrochemicals, Polymer, Additives, Surfactants, Pigments, Dyes, etc. Promoters are First Generation Technocrats with sound entrepreneurial Skills. Manufacturing units of Global Scale & Size and are situated in the State of Gujarat, Maharashtra, Madhya Pradesh and U.T. of Silvassa. Highly integrated Plants with Cost-Efficient Manufacturing Process,. Pioneer to introduce latest technology and manufacturing processes in India with the help of World Class R & D Globally ranks at 1 st – 5 th Position for majority of its key products Aarti Industries - Profile 3

4 Presence in high margin specialty chemicals with diverse applications Global Scale Units Manufacturing more than 125 products Ability to Supply Basket of products to Global Customers & MNCs Tagged as “Strategic Supplier” by various Global MNCs Backward Integration Latest Manufacturing Technology & World Class R&D Superior Cost Management Skills & Economies of Scale Capability to convert by-products into commercially viable product IPRs for Developing Customized Products & Products under Secrecy Agreements Captive Power Plants Core Strengths 4

5 Product & Process Flexibility A significant portion of Aarti’s Production capabilities are process driven and not based on a particular product. This gives Aarti the flexibility to change its input mix and manufacture different products, thereby resulting into optimum utilization of production capabilities Brief Structure of Aarti Industries’ Production Capabilities 5

6 Performance Polymer & additives Dyes, Pigments, Paints & Printing Inks Rubber chemicals, Resins, etc. Home & Personal Care Non-ionic Surfactants Concentrates for shampoo, hand wash & dish wash Agro-ingredients & Fertilizers Fertilizer Nutrients Agrochemicals & intermediates Pharmaceuticals Active Pharmaceutical Ingredients (APIs) CRAMS Segmental overview 6

7 Q3 FY13 Segmental Performance (standalone) Particulars PerformanceAgroPharmaH&PCTotal Income 27,993 10,1544,3873,402 45,936 % of Total Income 60.94%22.10%9.55%7.41%100.00% Export 15,3495,0801, ,540 % of Sales 54.83%50.03%39.41%11.26% 49.07% EBIT 4,062 1, ,148 EBIT Margin 14.51%18.05%3.74%2.63%13.38% In Rs. Lakh 7

8 Condensed Statement of Operations (standalone) Particulars Q3FY13 % of Total Income Q3FY12 % of Total Income Y-o-Y Growth (%) Income from Operations 44, % 40, %10.65% Other Operating Income %1, %(17.28%) Total Income 45, % 41, %9.89% Exports 22, %19, %18.59% Operating Expenditure 39, %35, %11.31% EBITDA 6, %6, %2.28% Depreciation 1, %1, %22.15% Other Income %250.06%268.00% EBIT 5, %5, %(1.65%) Finance Cost 2, %1, %13.11% Profit Before Tax 3, %3, %(9.51%) Tax Expenses %1, %(18.55%) Profit After Tax 2, %2, %(5.17%) In Rs. Lakh 8

9 Segmental Revenue Growth Trend (standalone) In Rs. Lakh 9 Segments Q1 FY12 Q2 FY12 Q3 FY12 Q4 FY12 Annual FY Q1 FY13 Q2 FY13 Q3 FY13 Performance Chemicals 26,11323,37123,53523,77996,79825,40928,451 27,993 Agri-Intermediates & Fertilisers 6,0478,44110,07213,67038,23010,46610,384 10,154 Pharmaceuticals 3,5653,8344,1284,93516,4624,8034,284 4,387 Home & Personal Care 3,2314,2514,0664,29315,8414,2113,843 3,402 Total Income 38,95639,89741,80146,677167,33144,88946,962 45,936

10 Particulars Q1 FY12 Q2 FY12 Q3 FY12 Q4 FY12 Annual FY11-12 Q1 FY13 Q2 FY13 Q3 FY13 Total Income 38,95639,89741,80146,677167,33144,88946,96245,936 Exports 16,45016,48419,00720,83572,77621,74923,64522,540 % of Total Inc %41.32%45.47%44.64%43.49%48.45%50.35%49.07% EBITDA 5,3965,3576,5657,14724,4656,8117,3926,715 EBITDA Margin 13.85%13.43%15.71%15.31%14.62%15.17%15.74%14.62% EBIT 4,2634,0945,2225,77319,3525,5045,9305,136 EBIT Margin 10.94%10.26%12.49%12.37%11.57%12.26%12.63%11.18% PAT 1,8071,7872,3012,8248,7192,5042,8262,182 PAT Margin 4.64%4.48%5.50%6.05%5.21%5.58%6.02%4.75% EPS In Rs. Lakh Financial Highlights – over 7 quarters (standalone)

11 11 Financial Highlights – Graphical Layout…1 (standalone) Total Income (Rs. Lakh) EBITDA (Rs. Lakh) & EBITDA as a %Net Profit (Rs. Lakh) Exports (Rs. Lakh) & Exports as % of Total Income

12 12 The Board of Directors have declared an interim dividend of Rs 1.25, for each equity shares of Rs 5. This is the second interim dividend declared by the board this fiscal aggregating to a total interim dividend of Rs 2.75 for each equity share of Rs.5. Commissioning of additional Hydrogenation unit at Jhagadia thereby increasing the production capabilities from 1,500 tpm to 3,000 tpm Commissioning of backward integrated Hydrogen Gas Generation plant at Jhagadia. Production of 1,400 tpm of hydrogenated products in Q3FY13. The Board of Directors have declared an interim dividend of Rs 1.25, for each equity shares of Rs 5. This is the second interim dividend declared by the board this fiscal aggregating to a total interim dividend of Rs 2.75 for each equity share of Rs.5. Commissioning of additional Hydrogenation unit at Jhagadia thereby increasing the production capabilities from 1,500 tpm to 3,000 tpm Commissioning of backward integrated Hydrogen Gas Generation plant at Jhagadia. Production of 1,400 tpm of hydrogenated products in Q3FY13. Key developments in Q3FY13

13 13 During the quarter, the company had taken a mandatory annual shutdown for maintenance of its Sulphuric Acid plant at Vapi. This had resulted for decline in topline and EBIDTA. EBIDTA from this unit was lower by approx Rs 4 crs in this qtr as compared to previous quarters. Commissioning of New Additional Hydrogenation Unit and backward integrated Hydrogen Gas Generation Plant in Q3 has resulted the increase in Depreciation and fixed overheads, while the benefits from these new capacities shall start from Q4FY13. During the quarter, the company had taken a mandatory annual shutdown for maintenance of its Sulphuric Acid plant at Vapi. This had resulted for decline in topline and EBIDTA. EBIDTA from this unit was lower by approx Rs 4 crs in this qtr as compared to previous quarters. Commissioning of New Additional Hydrogenation Unit and backward integrated Hydrogen Gas Generation Plant in Q3 has resulted the increase in Depreciation and fixed overheads, while the benefits from these new capacities shall start from Q4FY13. Key developments in Q3FY13

14 14 The Board of Directors, have approved an investment of Rs 35 crore for setting up a 200,000 tpa Single Super Phosphate unit at Jhagadia This unit shall consume the byproduct (i.e. Dilute Sulphuric Acid) generated at the existing / expanded manufacturing unit of the Company. The new unit is expected to be commissioned by Q4FY14. The Board of Directors, have approved an investment of Rs 35 crore for setting up a 200,000 tpa Single Super Phosphate unit at Jhagadia This unit shall consume the byproduct (i.e. Dilute Sulphuric Acid) generated at the existing / expanded manufacturing unit of the Company. The new unit is expected to be commissioned by Q4FY14. New Investments

15 15 Growth Drivers Exports led Growth: Growth in exports volume across various developed markets had been a key driver for increased operations. Flexibility to maximize margins – Interchangeable Production facilities of Performance & Agro- chemicals helps optimise the product mix to fetch better margins. Pharmaceuticals volume marginally lower due to debottlenecking exercise carried at one of unit. Growth momentum in pharmaceuticals segment to pickup

16 Thank You For further information please log on to or contact: Mr. Chetan Gandhi / Mrs. Mona Patel Tel: +91 (22) ; Mr. Siddharth Kumar / Mr. Dhiraj Rajpal Mobile: / /

17 Annexure – Financial Statements 17

18 18

19 19

20 Important Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with Bombay Stock Exchange and National Stock Exchange, and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the AARTI INDUSTRIES LIMITED. All information contained in this presentation has been prepared solely by AARTI INDUSTRIES LIMITED. AARTI INDUSTRIES LIMITED does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith. 20


Download ppt "PERFORMANCE REVIEW: Q3FY13 INVESTOR UPDATE. Presentation Path Aarti Industries – Profile Core Strengths Segmental overview Q3 FY13 Segmental Performance."

Similar presentations


Ads by Google